GLUE | Ticker Profile - Titan Protect

GLUE

Monte Rosa Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$16.37

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.56

Based on estimated future earnings — lower means cheaper

Rev Growth

-95.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-32.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.50

+86% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

https://www.monterosatx.com

Country: United States Employees: 187 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.175

Excellent risk-adjusted returns

Kelly Fraction

0.0976

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.886

Returns exceed worst-case losses — strong risk profile

Annual Return

121.2%

Historical annualised return based on price data

Max Drawdown

-64.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.62

Significantly more volatile than the market

52W High

$25.77

36% below the year high

52W Low

$3.90

320% above the year low

Avg Volume

982,332

Average daily shares traded — higher means easier to buy and sell

Short Ratio

18.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

18.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

7.49

Heavy leverage — higher financial risk if revenues decline

Current Ratio

9.54

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

9.44

Like current ratio but excludes inventory — stricter test

Gross Margin

-238.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,188.5%

Profit from core operations before interest and tax

Free Cash Flow

$-77,161,752

Negative — the business is spending more than it generates

Revenue (TTM)

$43M

Total revenue over the last 12 months

Net Income

$-130,014,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$37.00

Target Median

$30.50

Target Low

$29.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go